Please Wait
Applying Filters...
menu
    • menu

    List of Drug Master Files (DMF) of Hyoscine N-Butyl Bromide Active Pharmaceutical Ingredient (API) submitted to the U.S. FDA. Original Data : FDA Website

    Client Email Product
    DMF filings hit all-time high in Q3 2024; China tops list with 58% increase in Type II submissions

    Data Compilation
    #PharmaFlow

    Pipeline Prospector Sept 2024: BMS wins landmark FDA approval for schizophrenia med; Sanofi’s Dupixent okayed for COPD

    Stock Recap
    #PipelineProspector

    Menu

    Hyoscine N-Butyl Bromide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,346Xls download

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Data in the table can be downloaded after upgrading. In the meantime, you can access the data through the menu.

    Last Updated on PharmaCompass Virtual Booth Country Holder DMF No. Subject Submission Date Status Type GDUFA DMF Review GDUFA Review Date GDUFA Payment Date
    28/10/2024 Boehringer Ingelheim GmbH
    Germany
    		 BOEHRINGER INGELHEIM PHARMA KG 11679 SCOPOLAMINE-N-BUTLYBROMIDE (BUSCOPAN) 1995-09-20 Inactive II N/A
    28/10/2024 Vital Laboratories Private Limited
    India
    		 VITAL LABORATORIES PVT LTD 24477 SCOPOLAMINE BUTYL BROMIDE (HYOSCINE BUTYL BROMIDE) 2010-10-01 Active II N/A